-
Cerca nel sito -
- Area Riservata
- Sostienici
-
EMA recommends crizotinib for treatment of patients with advanced IMT aged 6-18 years old.
Still no access in Europe to crizotinib for patients aged >18 years old, despite the CREATE study included patients ≥15 years old and no other ALK inhibitors are available for adult ALK-translocated IMT.
